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Background: An understanding of the kinetics of a biomarker is essential to its interpretation. Despite this, little
kinetic modelling of blood biomarkers can be found in the literature. S100b is an astrocyte related marker of
brain injury used primarily in traumatic brain injury (TBI). Serum levels are expected to be the net result of a
multi-compartmental process. The optimal sample times for TBI prognostication, and to follow injury development, are
unclear. The purpose of this study was to develop a kinetic model to characterise the temporal course of serum S100b
concentration after primary traumatic brain injury.
Methods: Data of serial serum S100b samples from 154 traumatic brain injury patients in a neurointensive care unit were
retrospectively analysed, including only patients without secondary peaks of this biomarker. Additionally, extra-cranial
S100b can confound samples earlier than 12 h after trauma and were therefore excluded. A hierarchical, Bayesian gamma
variate kinetic model was constructed and the parameters estimated by Markov chain Monte Carlo sampling.
Results: We demonstrated that S100b concentration changes dramatically over timescales that are clinically important for
early prognostication with a peak at 27.2 h (95 % credible interval [25.6, 28.8]). Baseline S100b levels was found to be 0.
11 μg/L (95 % credible interval [0.10, 0.12]).
Conclusions: Even small differences in injury to sample time may lead to marked changes in S100b during the first days
after injury. This must be taken into account in interpretation. The model offers a way to predict the peak and trajectory
of S100b from 12 h post trauma in TBI patients, and to identify deviations from this, possibly indicating a secondary event.
Kinetic modelling, providing an equation for the peak and projection, may offer a way to reduce the ambiguity in
interpretation of, in time, randomly sampled acute biomarkers and may be generally applicable to biomarkers with, in
time, well defined hits.
Keywords: S100b protein, Human, Traumatic brain injury, Biomarkers, KineticsBackground
Traumatic brain injury (TBI) is a major health problem
worldwide. Data on the true total cost of TBI in Europe
are incomplete but even excluding non-hospitalized pa-
tients are estimated to be around €33 billion [1]. The
brain is uniquely vulnerable to insult due to its high
metabolic rate and limited intrinsic energetic reserve,
and failure to detect secondary injuries early and act ac-
cordingly may contribute to death or serious disability.
This has serious socioeconomic implications: For indi-
viduals with severe TBI, disability and lost productivity* Correspondence: david.nelson@karolinska.se
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factor of 4 [2].
Severe primary injuries may evolve and be com-
pounded by subsequent secondary insults and a main
objective of neurointensive care unit (NICU) treatment
is to predict, detect and prevent further injury. It is
therefore of importance to be able to quantify and moni-
tor the effects of both primary and secondary insults
over time. Biomarkers of injury are of increasing clinical
interest and a number of relatively brain specific mole-
cules have been studied as potential markers of TBI
severity [3].
One of the most studied serum biomarkers is S100b, a
member of the S100 family proteins which have a wide
range of regulatory functions (see review by [4]). S100ble is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tein found predominantly in astrocytes. It has been im-
plicated in several cellular processes, particularly those
of calcium homeostasis and signal transduction. Levels
in the cerebrospinal fluid (CSF) after injury are typically
10–100 times higher than those found in serum [5]. Re-
lease into the serum after brain injury could theoretically
be the result of several factors including impaired blood
brain barrier integrity [6], CSF recirculation to blood via
venous drainage [7] and circulation through the recently
identified glymphatic system [8]. The rate and temporal
profile of release may possibly also be related to the in-
jury type [8, 9]. S100b elimination from serum is
thought to be mostly renal [10] with the serum half-life
to be in the vicinity of 30–90 min [11, 12].
Unfortunately, other sources of S100b including skel-
etal muscle, chondrocytes and adipocytes have also been
identified [13]. S100b is elevated after extracranial
trauma [14] and has also been suggested as marker of
malignant melanoma [15]. The extent of extracranial
confounding in polytrauma patients with TBI has been
discussed [16, 17], but studies suggest that extracranial
S100b is quickly eliminated [18, 19]. As a result serum
levels after 12 h are most related to TBI outcome [20].
Notwithstanding these caveats S100b has been repeat-
edly related to outcome in TBI studies [21] although this
finding has been inconsistent [22, 23].
If S100b levels change rapidly after injury, then mea-
sured concentrations will be very sensitive to sample
timing. We postulate that much of the diversity in S100b
findings may be due to a limited understanding of its ex-
tended release kinetics after TBI, and that the non-
standardized sample timing relative to the initial trauma
may contribute to diverging interpretations. If this is
correct then modelling the kinetics of S100b may signifi-
cantly increase our understanding of S100b as a bio-
marker. This study aims to better understand the
temporal changes of serum S100b levels after traumatic
brain injury by modelling the kinetics using a gamma
variate wash-in/out curve- the most plausible function
given the above understanding of S100b dynamics to
date.
Methods
This study was approved by the Stockholm County local
ethics committee (2009/1668-31/2). No consent was re-
quired for this retrospective study. Data from 388 pa-
tients ≥15 years of age treated for TBI at the Karolinska
University Hospital NICU were extracted from elec-
tronic hospital records between 1st January 2005 and
31st December 2009. Patients were treated with standard
NICU care as previously reported [20]. The patients in-
cluded in this study, in part, overlap two previously pub-
lished papers on S100b from this institute [20, 24].Serum S100b was routinely sampled upon ICU admis-
sion and approximately every 12 h during the ICU stay
and the time of blood sampling was carefully recorded.
The time of trauma was extracted from the Karolinska
TBI database, a prospectively collected and curated data-
base where timings are determined from emergency call
and automated ambulance call times.
Two immunoassay methods were used during the
study period due to a change in analysis provided at the
Dept. of Clinical Chemistry laboratory. Samples through
Sept. 2008 were analysed with LIASON-mat S100 sys-
tem (Diasorin, Sangtec, Italy) and thereafter with Elecsys
S100b (Roche Diagnostics, Penzberg Germany). The
Elecsys method may exhibit somewhat lower levels,
compared to the LIASON-mat, especially at high con-
tractions of S100b [25, 26]. However, good congruence
between these methods has also been seen [27, 28] as
did the overlap period at the Clinical Chemistry labora-
tory, Karolinska University Hospital (unpublished re-
sults, internal validation report).
Only data 12 h post injury was included in our ana-
lysis, as we have previously shown that levels prior to
this are poorly related to outcome probably due to con-
tributions from extracranial trauma [20]. Additionally,
patients with obvious evidence of secondary injury de-
fined as an S100b increase after peak of >0.05 μg/L/12 h
and outliers with uncharacteristic curves were excluded
(7 patients). Furthermore, patients were required to have
at least 3 samples of S100b and starting within 48 h of
trauma. 154 of the original 388 admitted patients during
this period remained for the final statistical analysis.
Statistical analysis
We chose to model the time dependence of the S100b
concentration for the i-th patient (Si) as a function of
time (t) as a gamma variate function.
Si tð Þ ¼ Aitaexp ‐t=βð Þ þ B ð1Þ
This is a hierarchical model where Ai represents a
patient-specific amplitude related to the severity of their
individual insult and B is a baseline physiological S100b
level for the population as a whole. The gamma variate
is the most simple stochastic model describing a wash-
in/out curve [29] and has a characteristic peak-tail
shape. The population kinetic parameters α and β con-
trol the shape of the curve. It can be shown that α may
be interpreted as depending on the number of theoret-
ical “mixing chambers” or turbulence in the mixing
process and β is related to the ratio of mixing chamber
volume to flow [30]. In the limit of no mixing chambers
(i.e. an elimination process only), α becomes 0 and thus
Equation 1 reduces to the form of a decaying exponen-
tial with rate constant 1/β as expected. It can be shown
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curs at time tpeak = αβ in this model.
The two parameters α and β are antagonistic and fit-
ting of data to the gamma variate function using trad-
itional computer techniques is well known to be
extremely difficult due to numerical instability, which
limits convergence. Because of this and because esti-
mates of the posterior distributions of the parameters
and peak time/credible intervals are of clinical interest,
we developed a novel nested Bayesian approach.
Markov chain Monte Carlo (MCMC) simulations were
carried out using JAGS (version 3.1.0) [31] sampler and
rjags package within the R statistical programming lan-
guage [32]. We used non-informative Gaussian priors
for Ai, α and β. We chose non-informative gamma func-
tion distributions as priors, B and for our estimation of
tpeak. We demonstrated stability after a 1,000 round
burn-in and estimated parameters using three chains
over 20,000 iterations each.Results
Patient characteristics
See Table 1 for demographics. The 154 included patients
had a mean age of 45 years (range 15–84) and 81 % were
males. The median Glasgow Coma Scale (GCS) was 7.
Histogram/barplots of age, admission Glasgow Coma
Scale (GCS), pupil responses and Glasgow Outcome
Scales (GOS) are presented in Fig. 1a-d showing a 9.7 %
mortality and 60 % favourable outcome (GOS > 3).Kinetics of S100b
From our MCMC simulations, we obtained posterior es-
timates for the mean values of α = 0.69 (s.d. 0.042; 95 %
credible interval [0.61, 0.77]) and β = 1.65 day−1 (s.d.
0.057; 95 % credible interval [1.54, 1.76]). The mean fit-
ted time to peak was tpeak = 27.2 h (s.d. 0.82; 95 % cred-
ible interval [25.6, 28.8]).Table 1 Demographics
Gender male 81 %
Age (mean) 45
Admission GCS (median) 7
Pupil unilaterally responsive 15 %
Pupils unresponsive 5.3 %
Major Multi-trauma (ATLS criterion) 47 %
Epidural hematoma 23 %
Subdural hematoma 66 %
Traumatic subarachnoid haemorrhage 67 %
Contusion 67 %
Bleeding progression between CT scans 56 %The mean background S100b level was estimated to
be 0.11 μg/L (s.d. 0.0053; 95 % credible interval [0.10,
0.12]).
Figure 2 shows the posterior prediction for S100b as a
function of time with 95 % prediction intervals. This
takes into account the variability in the fitted values of
α, β and B constrained by the functional form of equa-
tion 1. Subject to this constraint, the estimated parame-
ters produce a very tight fit for the average kinetic
behaviour.
Figure 3 shows the predicted model with normalised
individual patient trajectories and overlaid gamma
model. From this plot it can be seen that the data gener-
ally fits the functional form of Equation 1 well although
there is additional inter-patient variability. As the data is
rescaled, by patient, some patients will appear to have
secondary peaks that in absolute numbers do not exceed
the exclusion criteria of >0.05 μg/L.
Discussion
We have demonstrated that S100b varies strongly with
time in the first few days after trauma, with a peak just
after day 1. From Fig. 2 it is clear that even excluding in-
dividual variability, the rapidly changing concentrations
predicted by the kinetics mean that even relatively small
differences in sampling time lead to very different mea-
surements, particularly in the first days after injury. This
has clear implications for clinical practice and research
studies using S100b.
For measurements to be comparable, the timing of
early S100b measurements after injury should ideally be
standardised- this would be difficult to achieve in clinical
practice. Our model offers a method to correct for dif-
ferences in sampling time. Furthermore, an approach
such as ours could find novel application in the detec-
tion of subsequent secondary injuries from serial S100b
measurements. Given any S100b level >12 h post-injury,
deviation of subsequent measurements from the stand-
ard kinetic curve over time would be an indicator that a
new injury had taken place. Conversely, levels of S100b
following the standard curve are reassuring; potentially
justifying relaxation of therapeutic targets under circum-
stances where this may be causing systemic harm, thus
individualising treatments.
From our results, we suggest that kinetic studies of
biomarkers are essential before evaluation and that some
basic principles should be adhered to. Sampling a bio-
marker too infrequently leads to misinterpretation. In
our study, the half time of S100b in serum, which is
known to be short, does not explain the values after the
initial trauma peak and they must be seen as the net of a
slow release process, and possible production, from the
injured site in a multi-compartment model. The infor-
mation content of a biomarker will be related to these
Fig. 1 Demographics. a Age (b) Glasgow Coma Scale (GCS) at admission (c) Pupil responses: Normal, One responsive, Non-responsive (d) Glasgow
Outcome Scale (GOS) barplot.(GOS 1 = dead - GOS 5 = full recovery)
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poral profiling of a biomarker should be oversampled
at a frequency exceeding the characteristic timescale
by 2–3 times by analogy with Nyquist-Shannon limit
from signal theory [34].
To our knowledge, this is the first study that has
attempted to quantify the kinetics of a clinical biomarker
in terms of a kinetic model. Additionally, as far as we
are aware, this is the first time that such a wash-in/
wash-out model which is known to be mathematically
problematic has been fitted to observational data using a
Bayesian/MCMC approach to yield estimates of the pos-
terior parameter distributions. Such an approach enables
the S100b level to be evaluated for any sampling timeafter a discrete insult such as occurs in trauma. Such a
methodology may find applications not just to TBI, but
also in the interpretation of S100b after other acute
brain syndromes and perhaps in other acute biomarkers
outside neuroscience.
This work is necessarily based on an analysis of obser-
vational data leading to some limitations. In particular,
since there is no accepted gold standard for assessing
secondary injury it is therefore likely that some of the
patients did experience secondary insults, which will dis-
tort our estimates of the kinetic parameters. Whilst we
cannot quantify this effect we would not expect this to
have a great effect on our estimate of the time to peak.
Furthermore, the presence of secondary injuries in our
Fig. 2 Fitted kinetic gamma variate model. Calculated mean of S100b posterior prediction distribution as a function of time from our model. The
dotted lines represent 95 % prediction intervals and within our model are interpreted as the parameter uncertainties excluding the variation from
individual patients
Ercole et al. BMC Neurology  (2016) 16:93 Page 5 of 8data would principally be expected to contribute to a
slower decay and therefore our estimate in some sense
represents an ‘upper bound’ to S100b kinetics. In other
words, whilst we cannot entirely exclude secondary in-
juries in a hypothetical patient following the same trajec-
tory as our model, a patient with S100b decreasing less
quickly than in our model (or increasing) would be very
suggestive of on-going damage i.e. such a temporal be-
haviour would be highly specific for secondary injury.
It is plausible that the prognostic potential of bio-
markers such as S100b would be improved by correcting
for the exact timing of the sample using knowledge of
the kinetics such as from our study. Alternatively, it
seems reasonable that the initial insult of the j-th patient
would be better described by an estimate of Aj (i.e. insultFig. 3 Plot of S100b trajectories for all patients. Re-scaled and translated to
model curve is overlaidis related to multiples of the standard value) or the area
under the expected curve or the true peak height (both
calculable from the model). Our current dataset is too
small to confirm this; we are currently collecting a data-
set, which we hope will allow us to validate this.
Other studies [35, 36] have observed S100b to follow a
simple exponential decay function. However, these
works have included very early S100b values, which we
argue may in fact be of extracranial origin and should
therefore be excluded. Furthermore, most previous work
has aggregated early S100b data too coarsely in time to
be able to clearly resolve the peak around 27 h. We
speculate that S100b from extracranial origin would have
an early and fast release to plasma and therefore mimic
a first order kinetic with exponential decay. Thus twominimise mean-square deviation from the from the model curve. The
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arated. For the slow release process from brain, we have
assumed a more sophisticated kinetic model based on
the gamma variate. This has the physical interpretation
of assuming that S100b kinetics obeys a wash-in/out
process with multiple theoretical compartments in series
and would therefore seem physically justified. As we
have stated previously, simple exponential elimination is
a special case of our model with α = 0. However, since
our 95 % credible interval for this parameter do not in-
clude zero, this provides strong evidence for wash-in/out
behaviour. More complex models are of course conceiv-
able. However we do not have data to motivate the
choice of any particular alternative and less parsimoni-
ous model.
Figure 3 shows that there is considerable variability in
the true patient data in addition to that explained by
variability the model parameters (Fig. 2). Several factors
that could affect the accuracy of the model therefore de-
serve further consideration. First, we have not evaluated
the influence of injury type on the kinetics properties.
Hermann et al. [9] have suggested that the time of peak
may vary with CT findings. It is probable that S100b re-
lease after an epidural hematoma has a different time
profile than a contusion or, for example, early typical
ICP related art. cerebri posterior infarction. The lack of
an unambiguous way of classifying injury type suggests
that a very large dataset would be required to address
this question specifically. Additionally, the sampling fre-
quency of S100b of around 12 h intervals chosen at our
institution is arbitrary and it is possible that a higher
sampling rate would help to better model S100b kinetics.
However, by chance this is found to be 2.25 the peak
time and would therefore seem adequate, if slightly on
the low side. Finally, the modelling of the offset value
does not extend beyond the NICU period of acute dam-
age. The baseline found in our study of 0.11 μg/L (s.d.
0.0053 μg/L; 95 % credible interval [0.010, 0.12]), is close
to the normal reference values of the analysis method
(Roche <0.10 μg/L) suggesting a limited effect of the pri-
mary injury on S100b levels after 10–15 days.
As stated previously, two different laboratory assays
were used to measure S100b during the study period.
If of significance, this would be expected to broaden
the limits of confidence of the model, which are tight.
We are therefore fairly confident that this is not a
major limitation. Another factor that could broaden
these intervals is uncertain trauma origin times. Given
that these are given from ambulance alert times there
may be some variation in the timing of trauma to
alert time and this would cause a more uncertain
peak time. Again, given the tight intervals of the
model this would not appear to be a serious
limitation.In addition to S100b, a large number of other brain in-
jury biomarkers including neurofilament (NF), glial fi-
brillary acidic protein (GFAP), ubiquitin carboxyl
terminal hydrolase-L1 (UCH-L1), spectrin breakdown
products, cleaved tau (C-tau), neuron specific enolase
(NSE) are known and seem to have subtly different
pathobiological sensitivities [3], although all respond in
some gross way to brain injury. It therefore seems likely
that the greatest diagnostic potential will come from
studying panels of different markers, enabling clinicians
to exploit differences between them to better character-
ise injury processes. However, since these differences
seem to be subtle, a fuller characterisation of the kinetics
of these other biomarkers in different disease states is
likely to be important too.
Conclusions
We have modelled the serum kinetics of S100b demon-
strated that it changes rapidly in the first days after injury.
The interpretation of the biomarker level in relation to the
primary injury will therefore be highly influenced by the
time from trauma and even small differences in timings
may lead to inaccurate assessment of the magnitude of the
injury. This has been little explored in the biomarker litera-
ture and may greatly affect the results and possibly inter-
pretations of other studies. We have demonstrated that
S100b concentrations vary rapidly in the first 24–48 h after
injury indicating that an optimal and standardized window
for sampling must be identified. Alternatively, if variably
timed measurements of S100b are to be used for prognosti-
cation or research it is crucial to take the timing into ac-
count by comparison with a reference curve such as the
one presented in this work. Furthermore, monitoring for
systematic deviations above the predicted curve in serial
measurements may offer a clinical method for detecting the
occurrence of secondary injuries. Further validation against
outcome is required. However, we believe that kinetic con-
siderations are of general importance when using bio-
markers with rapidly changing levels over timescales of
clinical interest.
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